Tgfβ-Smad and MAPK signaling mediate scleraxis and proteoglycan expression in heart valves

Journal of Molecular and Cellular Cardiology

Volumn 65, Issue , 2013, Pages 137-146

  Barnette, Damien N ^a,b,c   Hulin, Alexia ^d   Ahmed, A S Ishtiaq ^e   Colige, Alain C ^d   Azhar, Mohamad ^e   Lincoln, Joy ^b,c,f  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

Author keywords

Heart valve; MAPK; Myxomatous; Proteoglycan; Scleraxis; Tgf

Indexed keywords

CHONDROITIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEOCHONDROITIN SULFATE; SCLERAXIS; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HEART DEVELOPMENT; HEART VALVE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SWINE; UPREGULATION;

AVES; MUS; SUS;

HEART VALVE; MAPK; MYXOMATOUS; PROTEOGLYCAN; SCLERAXIS; TGFΒ;

ANIMALS; ANIMALS, NEWBORN; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CHICKENS; DISEASE MODELS, ANIMAL; HEART VALVES; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MITRAL VALVE; NIH 3T3 CELLS; PROTEOGLYCANS; SMAD PROTEINS; SUS SCROFA; TRANSFORMING GROWTH FACTOR BETA;

EID: 84887141758     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.10.007     Document Type: Article

References (44)

1. Lincoln J., Yutzey K.E. Molecular and developmental mechanisms of congenital heart valve disease. Birth Defects Res A Clin Mol Teratol 2011, 91:526-534.
2. Guy T.S., Hill A.C. Mitral valve prolapse. Annu Rev Med 2012, 63:277-292.
3. Nasuti J.F., Zhang P.J., Feldman M.D., Pasha T., Khurana J.S., Gorman J.H., et al. Fibrillin and other matrix proteins in mitral valve prolapse syndrome. Ann Thorac Surg 2004, 77:532-536.
4. Akhtar S., Meek K.M., James V. Ultrastructure abnormalities in proteoglycans, collagen fibrils, and elastic fibers in normal and myxomatous mitral valve chordae tendineae. Cardiovasc Pathol 1999, 8:191-201.
5. Olsen E.G., Al-Rufaie H.K. The floppy mitral valve. Study on pathogenesis. Br Heart J 1980, 44:674-683.
6. Kinsella M.G., Bressler S.L., Wight T.N. The regulated synthesis of versican, decorin, and biglycan: extracellular matrix proteoglycans that influence cellular phenotype. Crit Rev Eukaryot Gene Expr 2004, 14:203-234.
7. Gupta V., Barzilla J.E., Mendez J.S., Stephens E.H., Lee E.L., Collard C.D., et al. Abundance and location of proteoglycans and hyaluronan within normal and myxomatous mitral valves. Cardiovasc Pathol 2009, 18:191-197.
8. Cserjesi P., Brown D., Ligon K.L., Lyons G.E., Copeland N.G., Gilbert D.J., et al. Scleraxis: a basic helix-loop-helix protein that prefigures skeletal formation during mouse embryogenesis. Development 1995, 121:1099-1110.
9. Edom-Vovard F., Schuler B., Bonnin M.A., Teillet M.A., Duprez D. Fgf4 positively regulates scleraxis and tenascin expression in chick limb tendons. Dev Biol 2002, 247:351-366.
10. Schweitzer R., Chyung J.H., Murtaugh L.C., Brent A.E., Rosen V., Olson E.N., et al. Analysis of the tendon cell fate using Scleraxis, a specific marker for tendons and ligaments. Development 2001, 128:3855-3866.
11. Brent A.E., Schweitzer R., Tabin C.J. A somitic compartment of tendon progenitors. Cell 2003, 113:235-248.
12. Brent A.E., Tabin C.J. FGF acts directly on the somitic tendon progenitors through the Ets transcription factors Pea3 and Erm to regulate scleraxis expression. Development 2004, 131:3885-3896.
13. Shukunami C., Takimoto A., Oro M., Hiraki Y. Scleraxis positively regulates the expression of tenomodulin, a differentiation marker of tenocytes. Dev Biol 2006, 298:234-247.
14. Espira L., Lamoureux L., Jones S.C., Gerard R.D., Dixon I.M., Czubryt M.P. The basic helix-loop-helix transcription factor scleraxis regulates fibroblast collagen synthesis. J Mol Cell Cardiol 2009, 47:188-195.
15. Smith T.G., Sweetman D., Patterson M., Keyse S.M., Munsterberg A. Feedback interactions between MKP3 and ERK MAP kinase control scleraxis expression and the specification of rib progenitors in the developing chick somite. Development 2005, 132:1305-1314.
16. Murchison N.D., Price B.A., Conner D.A., Keene D.R., Olson E.N., Tabin C.J., et al. Regulation of tendon differentiation by scleraxis distinguishes force-transmitting tendons from muscle-anchoring tendons. Development 2007, 134:2697-2708.
17. Bagchi R.A., Czubryt M.P. Synergistic roles of scleraxis and Smads in the regulation of collagen 1alpha2 gene expression. Biochim Biophys Acta 1823, 2012:1936-1944.
18. Levay A.K., Peacock J.D., Lu Y., Koch M., Hinton R.B., Kadler K.E., et al. Scleraxis is required for cell lineage differentiation and extracellular matrix remodeling during murine heart valve formation in vivo. Circ Res 2008, 103:948-956.
19. Ng C.M., Cheng A., Myers L.A., Martinez-Murillo F., Jie C., Bedja D., et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004, 114:1586-1592.
20. Azhar M., Brown K., Gard C., Chen H., Rajan S., Elliott D.A., et al. Transforming growth factor Beta2 is required for valve remodeling during heart development. Dev Dyn 2011, 240:2127-2141.
21. Huk D.J., Hammond H.L., Kegechika H., Lincoln J. Increased dietary intake of vitamin A promotes aortic valve calcification in vivo. Arterioscler Thromb Vasc Biol 2013, 33:285-293.
22. Lincoln J., Alfieri C.M., Yutzey K.E. BMP and FGF regulatory pathways control cell lineage diversification of heart valve precursor cells. Dev Biol 2006, 292:292-302.
23. Bueno O.F., De Windt L.J., Tymitz K.M., Witt S.A., Kimball T.R., Klevitsky R., et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000, 19:6341-6350.
24. Liang Q., De Windt L.J., Witt S.A., Kimball T.R., Markham B.E., Molkentin J.D. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem 2001, 276:30245-30253.
25. Hulin A., Deroanne C.F., Lambert C.A., Dumont B., Castronovo V., Defraigne J.O., et al. Metallothionein-dependent up-regulation of TGF-beta2 participates in the remodelling of the myxomatous mitral valve. Cardiovasc Res 2012, 93:480-489.
26. Gould R.A., Butcher J.T. Isolation of valvular endothelial cells. J Vis Exp 2010, 46.
27. Peacock J.D., Levay A.K., Gillaspie D.B., Tao G., Lincoln J. Reduced sox9 function promotes heart valve calcification phenotypes in vivo. Circ Res 2010, 106:712-719.
28. Bosse K., Hans C.P., Zhao N., Koenig S.N., Huang N., Guggilam A., et al. Endothelial nitric oxide signaling regulates Notch1 in aortic valve disease. J Mol Cell Cardiol 2013, 60:27-35.
29. Farhat Y.M., Al-Maliki A.A., Chen T., Juneja S.C., Schwarz E.M., O'Keefe R.J., et al. Gene expression analysis of the pleiotropic effects of TGF-beta1 in an in vitro model of flexor tendon healing. PLoS One 2012, 7:e51411.
30. Mendias C.L., Gumucio J.P., Lynch E.B. Mechanical loading and TGF-beta change the expression of multiple miRNAs in tendon fibroblasts. J Appl Physiol 2012, 113:56-62.
31. Lorda-Diez C.I., Montero J.A., Martinez-Cue C., Garcia-Porrero J.A., Hurle J.M. Transforming growth factors beta coordinate cartilage and tendon differentiation in the developing limb mesenchyme. J Biol Chem 2009, 284:29988-29996.
32. Zhao B., Etter L., Hinton R.B., Benson D.W. BMP and FGF regulatory pathways in semilunar valve precursor cells. Dev Dyn 2007, 236:971-980.
33. Reznikoff C.A., Bertram J.S., Brankow D.W., Heidelberger C. Quantitative and qualitative studies of chemical transformation of cloned C3H mouse embryo cells sensitive to postconfluence inhibition of cell division. Cancer Res 1973, 33:3239-3249.
34. Krenz M., Yutzey K.E., Robbins J. Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling. Circ Res 2005, 97:813-820.
35. Molin D.G., Bartram U., Van der Heiden K., Van Iperen L., Speer C.P., Hierck B.P., et al. Expression patterns of Tgfbeta1-3 associate with myocardialisation of the outflow tract and the development of the epicardium and the fibrous heart skeleton. Dev Dyn 2003, 227:431-444.
36. Robbins J.R., Evanko S.P., Vogel K.G. Mechanical loading and TGF-beta regulate proteoglycan synthesis in tendon. Arch Biochem Biophys 1997, 342:203-211.
37. Kretzschmar M., Doody J., Timokhina I., Massague J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev 1999, 13:804-816.
38. Hough C., Radu M., Dore J.J. Tgf-beta induced Erk phosphorylation of smad linker region regulates smad signaling. PLoS One 2012, 7:e42513.
39. Edom-Vovard F., Bonnin M., Duprez D. Fgf8 transcripts are located in tendons during embryonic chick limb development. Mech Dev 2001, 108:203-206.
40. Dietz H.C., Cutting G.R., Pyeritz R.E., Maslen C.L., Sakai L.Y., Corson G.M., et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991, 352:337-339.
41. Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T., et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005, 37:275-281.
42. Matt P., Schoenhoff F., Habashi J., Holm T., Van Erp C., Loch D., et al. Circulating transforming growth factor-beta in Marfan syndrome. Circulation 2009, 120:526-532.
43. Holm T.M., Habashi J.P., Doyle J.J., Bedja D., Chen Y., van Erp C., et al. Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 2011, 332:358-361.
44. Radermecker M.A., Limet R., Lapiere C.M., Nusgens B. Increased mRNA expression of decorin in the prolapsing posterior leaflet of the mitral valve. Interact Cardiovasc Thorac Surg 2003, 2:389-394.